Aspen to cut prices of off-patent cancer medicines
Aspen Pharmacare has reached a deal with the European Commission (EC) to reduce prices for six off-patent cancer medicines by 73% in Europe, addressing excessive pricing concerns. (Business Day 10 February 2021)
This follows an investigation into claims that Aspen might have abused its dominant position by imposing unfair prices. Aspen said it disagreed with the commission’s preliminary assessment last year in July, but in order to meet the commission’s competition concerns, the group proposed cutting its prices by between 27% and 79%.
• Meanwhile, Aspen announced that its deputy CEO and co-founder Gus Attridge will retire at the end of 2021.